SUZHOU, China, and ROCKVILLE, MD, US, July 21, 2021 — Ascentage Pharma (6855.HK), a globally focused biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) recently granted an Orphan Drug Designation (ODD) to the company’s MDM2-p53 inhibitor, APG-115 Read More ›

SUZHOU, China, and ROCKVILLE, MD, US, July 19, 2021 — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of National Read More ›

SUZHOU, China, and ROCKVILLE, MD, US, July 14, 2021 — Ascentage Pharma (6855.HK), a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics (1801.HK, “Innovent”), today announced a multifaceted strategic collaboration. This collaboration includes the joint clinical development and commercialization of HQP1351(olverembatinib), a Read More ›

SUZHOU, China, and ROCKVILLE, MD, US, June 14, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational New Drug (IND) application for the company’s novel Bcl-2 inhibitor, lisaftoclax (APG-2575), has been cleared by the Read More ›

SUZHOU, China, and ROCKVILLE, MD, US, June 7, 2021—Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released updated results from the first-in-human study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R Read More ›

SUZHOU, China, and ROCKVILLE, MD, US, June 7, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today presented in an oral presentation at the 57th American Society of Clinical Oncology (ASCO) Annual Meeting, updated results from a Phase Read More ›

Dr. Ming Guo, Co-Founder, President and Chief Operating Officer of Ascentage Pharma (on the left), and Dr. Minzhang Chen, Chief Executive Officer of WuXi STA (on the right) SUZHOU, China and ROCKVILLE, MD., U.S., June XX, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic Read More ›

SUZHOU, China and ROCKVILLE, MD., U.S., May 19, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts reporting on two clinical studies evaluating the company’s drug candidate, alrizomadlin (APG-115), have been published in the 2021 Read More ›

SUZHOU, China and ROCKVILLE, MD., U.S., May 19, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on the first-in-human study of the Bcl-2 inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory chronic lymphocytic Read More ›

SUZHOU, China and ROCKVILLE, MD., U.S., May. 13, 2021 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that according to the latest semi-annual index review results announced by MSCI, a leading provider of index services and analytics, Read More ›